Core Insights - The company has confirmed its financial guidance for 2025, narrowing organic revenue growth expectations to a range of -2% to +2% [8][12] - The Hearing division is expected to contribute organic revenue growth of 5% to 9%, but due to lower market growth assumptions, it is now anticipated to grow at the lower end of that range [5][4] - The Enterprise division is facing challenges due to market uncertainty, with expected organic revenue growth of -8% to 0% [6] - The Gaming division is also impacted by trade environment changes, with organic revenue growth now expected in the upper half of the range of -6% to +2% [7] Financial Performance - Group reported EBITA increased by 46% to DKK 546 million, with an EBITA margin of 13% [8] - Free cash flow excluding M&A was DKK 353 million, reflecting a positive earnings profile and working capital impact [8] - The Hearing division achieved 8% organic revenue growth, while the Enterprise division saw a decline of -7% [8][10] Market Conditions - The hearing aid market is projected to grow at 4-6% in volumes, driven by favorable demographic trends, but is expected to grow slower than its structural trend in 2025 [4] - The company is actively diversifying its manufacturing footprint and implementing price adjustments to mitigate impacts from the changing trade environment [6][9] - The overall impact of tariffs is expected to reduce the group EBITA margin by approximately -1% in 2025 [10]

Financial Data and Key Metrics Changes - The company reported record first quarter consolidated revenue of $251 million, a 4.5% increase year-over-year [16] - GAAP earnings from operations increased by 22.4% to $51 million, while adjusted EBITDA reached a record $66 million, up 8.9% [21][16] - Consolidated net income was $37 million, reflecting a 27.8% increase, translating to diluted net earnings per share of $1.13, up 27% [23][17] Business Segment Performance - The Human Nutrition & Health segment generated record sales of $158 million, a 3.7% increase, with earnings from operations rising 14.2% to $38 million [24][25] - The Animal Nutrition & Health segment saw sales of $57 million, up 6.2%, with earnings from operations increasing 154.2% to $5 million [26][27] - The Specialty Products segment delivered sales of $33 million, a 5.3% increase, with earnings from operations rising 16.9% to $10 million [29][30] Market Data and Key Metrics Changes - The company imports approximately $100 million of raw materials annually, with less than $15 million from China, indicating a diversified supply chain [11] - The impact of current tariffs is estimated at approximately $20 million, with the company planning to offset half through alternative sourcing and pricing actions [12] Company Strategy and Industry Competition - The company is well-positioned to manage the evolving global trade environment, leveraging a strong manufacturing footprint and supply chain flexibility [9][10] - The management expressed confidence in the long-term growth outlook, emphasizing the resilience of the business model amid market uncertainties [32] Management's Comments on Operating Environment and Future Outlook - Management noted that demand remains healthy across end markets, with no current signs of recessionary impacts affecting order books [43][44] - The company has a solid track record of delivering results in various market conditions, having achieved 23 consecutive quarters of year-over-year growth in adjusted EBITDA [45] Other Important Information - Cash flows from operations were reported at $36 million, with free cash flow of $31 million and $50 million in cash on the balance sheet [24] - The effective tax rate for the first quarter was 22.7%, with expectations for the full year to be in the range of 22% to 23% [22][73] Q&A Session Summary Question: Impacts of tariffs and trade war - Management acknowledged the complexity of tariff impacts but expressed confidence in their ability to manage costs through supply chain flexibility and pricing strategies [39][42] Question: Update on European Chinese dumping ruling - The company has filed an anti-dumping case accepted by the EU, with expectations for a response in the next three to six months [48][49] Question: Tailwinds for 2025 and product performance - Management highlighted strong growth in the choline and vitamin K2 categories, with expectations for continued growth driven by new product launches [58][60] Question: Debt repayment strategy - The company prioritizes organic growth investments and is evaluating M&A opportunities while continuing to pay down debt [70][71] Question: Effective tax rate expectations - The effective tax rate for the remainder of the year is expected to be around 22% to 22.5% based on first-quarter performance [73]

Financial Data and Key Metrics Changes - The company reported record first quarter consolidated revenue of $251 million, a 4.5% increase year-over-year [12][13] - GAAP earnings from operations increased by 22.4% compared to the prior year [13][18] - Adjusted EBITDA reached a record $66 million, up 8.9%, with an adjusted EBITDA margin of 26.5%, an increase of 106 basis points from the prior year [13][17] - Consolidated net income for the quarter was $37 million, a 27.8% increase, translating to diluted net earnings per share of $1.13, up 27% year-over-year [13][19] Business Segment Performance - The Human Nutrition and Health segment generated record sales of $158 million, a 3.7% increase, with earnings from operations of $38 million, up 14.2% [19][20] - The Animal Nutrition and Health segment reported sales of $57 million, a 6.2% increase, with earnings from operations of $5 million, up 154.2% [21][22] - The Specialty Products segment delivered sales of $33 million, a 5.3% increase, with earnings from operations of $10 million, up 16.9% [22][23] Market Data and Key Metrics Changes - The company imports approximately $100 million of raw materials annually, with less than $15 million from China, indicating a diversified supply chain [7][8] - The company exports approximately $90 million annually, with current tariffs having an immaterial impact on exports [10][11] Company Strategy and Industry Competition - The company is well-positioned to manage through the changing global trade environment, leveraging a strong manufacturing and sales model [6][12] - The management emphasized the ability to raise prices to offset tariff impacts, similar to actions taken during the post-COVID inflationary period [9][30] - The company is focusing on organic growth and evaluating M&A opportunities, with a cautious approach due to current market uncertainties [50][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's resilience amid evolving trade conditions, noting healthy demand across end markets [11][12] - The company is monitoring potential recessionary impacts on overall demand but currently sees no signs of demand weakening [11][31] - The management remains optimistic about growth in the Human Nutrition and Health segment, particularly in the Food Ingredients and Nutrients businesses [20][60] Other Important Information - The effective tax rate for the first quarter was 22.7%, with expectations for the full year to be in the range of 22% to 22.5% [18][53] - The company closed the quarter with $50 million in cash on the balance sheet and free cash flow of $31 million [19] Q&A Session Summary Question: Impact of tariffs and trade war - Management feels well-positioned to manage tariff impacts, expecting to offset half of the costs through supply chain flexibility and pricing actions [29][30] Question: Update on European Chinese dumping ruling - The company has filed an antidumping case accepted by the EU, expecting a response in three to six months, with confidence in the case's strength [35][36] Question: Tailwinds for 2025 - Management highlighted growth in choline and vitamin K2 categories, with strong demand and marketing efforts contributing to performance [40][42] Question: Debt repayment strategy - The company prioritizes organic growth investments, with ongoing debt repayment and potential share buybacks considered [50][52] Question: Breakdown of Human Nutrition and Health segment growth - The food ingredient business grew faster than the nutrients business, indicating strong performance across various product lines [58][60]